This review outlines a digital platform that improves data analysis and workflow management for large-molecule treatments, highlighting its capabilities.
The repertoire of large-molecule treatments continues to expand, resulting in diverse discovery and development workflows. This diversity yields a proliferation of software solutions and procedures for molecule registration, material tracking, experiment planning, data analytics, quality control, data sharing, and decision-making. Contrasting with this manual, labor intensive, and error-prone approach, we introduce the concept of a transformative solution: an integrated platform that translates this complexity into a harmonized, open architecture encompassing all workflows and hardware systems, covering the discovery process up to developability assessment. The benefits and complexities of such a platform are evident in examples spanning different use cases and maturity levels, such as developing multi-specific antibodies and antibody-drug conjugates using shared workflows or incorporating artificial intelligence for predictive and generative tasks. This review outlines state-of-the-art concepts behind a digital platform for automating and streamlining the discovery of new large-molecule treatments.
No takes yet. Share an insight, caveat, or question.
Natali et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: